Difficulty: Medium
Average Score: 68%
Practice
Indicate the long-acting neuromuscular blocking agent:
Correct answer
C
Rationale
In this question from the Pharmacology Across the Lifespan ATI exam, the correct answer is option C) Tubocurarine. Tubocurarine is a long-acting neuromuscular blocking agent that acts by competitively blocking acetylcholine receptors at the neuromuscular junction, leading to muscle paralysis.
Option A) Rapacuronium is not a long-acting neuromuscular blocking agent; it is actually a short-acting agent that has been associated with serious adverse effects and has been withdrawn from the market.
Option B) Mivacurium is an intermediate-acting neuromuscular blocking agent, not a long-acting one.
Option D) Rocuronium is an intermediate-acting neuromuscular blocking agent as well, not a long-acting one like Tubocurarine.
Understanding the differences between the various neuromuscular blocking agents is crucial for healthcare professionals, especially those involved in anesthesia and critical care settings. Knowing the characteristics of each drug helps in selecting the appropriate agent based on the clinical scenario and patient needs, ultimately ensuring safe and effective patient care.
Option A) Rapacuronium is not a long-acting neuromuscular blocking agent; it is actually a short-acting agent that has been associated with serious adverse effects and has been withdrawn from the market.
Option B) Mivacurium is an intermediate-acting neuromuscular blocking agent, not a long-acting one.
Option D) Rocuronium is an intermediate-acting neuromuscular blocking agent as well, not a long-acting one like Tubocurarine.
Understanding the differences between the various neuromuscular blocking agents is crucial for healthcare professionals, especially those involved in anesthesia and critical care settings. Knowing the characteristics of each drug helps in selecting the appropriate agent based on the clinical scenario and patient needs, ultimately ensuring safe and effective patient care.